On April 18, 2024, the Food and Drug Administration approved alectinib as an adjuvant treatment for patients with anaplastic lymphoma kinase ()-positive non-small cell lung cancer (NSCLC) after tumor resection. This approval was grounded in the outcomes of the ALINA trial, which demonstrated that alectinib significantly enhances disease-free survival compared to traditional platinum-based chemotherapy in the adjuvant setting. The ALINA trial is notable not just for advancing ALK tyrosine kinase inhibitors (TKIs) into the adjuvant setting but also for its innovative approach of comparing them to adjuvant chemotherapy, distinguishing it from other landmark trials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367166 | PMC |
| http://dx.doi.org/10.2147/LCTT.S478054 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A New Way Forward for Women's Health Research at the National Institutes of Health: A Roadmap From the National Academies of Sciences, Engineering, and Medicine's Consensus Report.
Obstet Gynecol
January 2025
Department of Obstetrics and Gynecology, Spencer Fox Eccles School of Medicine, University of Utah Health, Salt Lake City, Utah; the Department of Obstetrics and Gynecology, Warren Alpert Medical School at Brown University, and Women and Infants Hospital of Rhode Island, Providence, Rhode Island; the National Academies of Sciences, Engineering, and Medicine, and Baker Donelson, Washington, DC; KFF, San Francisco, California; and the Department of Obstetrics and Gynecology, Duke Cancer Institute, Duke School of Medicine, Durham, North Carolina. All authors served on the National Academies Committee as committee members or employees of the National Academies.
Despite efforts to address inequities, research on women's health conditions (defined as those that uniquely or differently affect women and female individuals) remain significantly understudied. As directed by Congress, the National Institutes of Health (NIH) Office of Research on Women's Health requested the National Academies of Sciences, Engineering, and Medicine (National Academies) to conduct an assessment of the state of women's health research at the NIH. The findings of the National Academies committee include: 1) a significant funding inequity, with less than 8% of the total NIH grant budget for fiscal year 2023 allocated to women's health research; 2) a need for improved strategic NIH-wide priority setting, oversight, and adherence to existing policies to support women's health research; 3) a need for a specific institute for research on conditions specific to women's health; and 4) a need for sufficient training and additional funding to grow and retain the women's health research workforce.
View Article and Find Full Text PDFSex-Specific Difference in Health-Related Altitude-Effects and Their Prevention by Acetazolamide. Data from a Randomized Controlled Trial.
High Alt Med Biol
January 2025
Department of Respiratory Medicine, University Hospital Zurich, Zurich, Switzerland.
Häfliger, Alina, Aline Buergin, Laura C. Mayer, Maamed Mademilov, Mona Lichtblau, Talantbek Sooronbaev, Silvia Ulrich, Konrad E. Bloch, and Michael Furian.
View Article and Find Full Text PDFHyporesponsiveness to Erythropoiesis-Stimulating Agents in Dialysis-Dependent Patients with Anaemia of Chronic Kidney Disease: A Retrospective Observational Study.
Adv Ther
November 2024
Fresenius Medical Care D GmbH, Bad Homburg, Germany.
Introduction: Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in patients with anaemia of chronic kidney disease may lead to increased ESA doses to achieve target haemoglobin levels; however, elevated doses may be associated with increased mortality. Furthermore, patients with hyporesponsiveness to ESAs have poorer clinical outcomes than those who respond well to ESAs. Incidence and clinical characteristics of patients with ESA hyporesponsiveness were explored in a real-world setting.
View Article and Find Full Text PDFAutoimmunity, a relevant exclusion criterion in the development of mRNA-based compounds: A systematic review of clinical trials registries.
Autoimmun Rev
December 2024
Clinical Department 5, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Departments of Internal Medicine and Rheumatology, Colentina Clinical Hospital, Bucharest, Romania.
Background: Messenger RNA (mRNA) -based compounds have been lately developed as one of the most promising treatment alternatives in a wide range of pathologies, especially cancers and infectious diseases.
Aim: To review the current research landscape on mRNA-based compounds, with a focus on the inclusion criteria used for participants with autoimmune diseases and/or under immunosuppressive treatments.
Methods: We conducted a comprehensive search based on PICO framework specifically formulated, throughout the most important clinical trial registries: WHO International Clinical Trials Registry Platform (ICTRP) portal, ClinicalTrials.
What do we know about the role of neoadjuvant targeted therapy in early-stage -mutant and -fused non-small cell lung cancer?-a narrative review of the current literature.
Transl Lung Cancer Res
October 2024
Department of Medicine A, Hematology, Oncology, Hemostaseology and Pulmonology, University Hospital Muenster, Muenster, Germany.
Background And Objective: The standard first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor () mutations or anaplastic lymphoma kinase () fusions is targeted therapy using tyrosine kinase inhibitors (TKIs). However, data are still lacking on the use of TKIs as a neoadjuvant or induction approach. Therefore, this narrative review aims to summarize the current knowledge on resectable -mutant and -fused NSCLC regarding available perioperative treatment regimens and off-label neoadjuvant use of targeted therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!